Pfizer Inc said on Monday it would acquire Array Biopharma Inc for $10.64 billion in cash, giving it access to the target’s approved drugs for skin cancer and the targeted cancer medicines in its pipeline.

Continue Reading Below

The offer of $48 per Array share represents a premium of about 62 percent to the stock’s close on Friday. Array’s shares surged 56 percent in light premarket trade.

MORE FROM FOXBUSINESS.COM